<DOC>
	<DOCNO>NCT02403349</DOCNO>
	<brief_summary>Confirm central blood pressure reduction effect Fimasartan , Valsartan Atenolol compare correlation measure peripheral ( central blood pressure , pulse wave velocity , flow-mediated dilation ) cerebral blood flow factor ( transcranial doppler finding , cerebral blood flow volume ) acute ischemic stroke patient hypertension .</brief_summary>
	<brief_title>Comparison Peripheral Cerebral Arterial Flow Acute Ischemic Stroke : Fimasartan vs. Valsartan vs. Atenolol</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Age ≥ 30 year old Acute ischemic stroke patient correspond DWI ( diffusion weight image ) lesion correlate symptom 7days , within 28days stroke onset Diagnosed Hypertension hypertensive patient take antihypertensive drug SBP≥140mmHg Informed consent Patients hemorrhagic Stroke Patients severe Stroke NIHss ( National Institutes Health stroke scale ) 16 Uncontrolled hypertension ( SBP ≥200mmHg ) Patients history allergic reaction angiotensin II antagonist Liver disease ( double normal level , SGOT ( serum glutamicoxaloacetic transaminase ) , SGPT ( serum glutamicpyruvic transaminase ) , total bilirubin ) Renal disease ( serum creatinine ≥2.0mg/dl ) Anemia ( Hb &lt; 8mg/dl ) Thrombocytopenia ( &lt; 10^3/ml ) Patients secondary hypertension Childbearing breastfeed woman Otherwise inappropriate patient depend investigator 's decision</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>